Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19

Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19

ABSTRACT Understanding immune memory to COVID-19 vaccines is critical for the design and optimal vaccination schedule for curbing the COVID-19 pandemic. Here, we assessed the status of humoral and cellular immune responses at 1, 3, 6, and 12 months after two-dose CoronaVac vaccination. A total of 15...

Descripció completa

Dades bibliogràfiques
Autors principals:	Wei Zhao, Weixin Chen, Juan Li, Meng Chen, Qin Li, Min Lv, ShanShan Zhou, Shuang Bai, Yali Wang, Lichi Zhang, Peng Zhang, Jian Wang, Qun Zheng, Jiang Wu
Format:	Article
Idioma:	English
Publicat:	American Society for Microbiology 2022-06-01
Col·lecció:	mBio
Matèries:	COVID-19 vaccine 12 months neutralizing antibody T cells CoronaVac
Accés en línia:	https://journals.asm.org/doi/10.1128/mbio.00181-22

Ítems similars

Safety and immunogenicity of CoronaVac in healthy adults: A prospective observational multicenter real-world study in Henan Province, China
per: Benchen Rao, et al.
Publicat: (2024-12-01)

Humoral Immune Response to CoronaVac in Turkish Adults
per: Yasemin Cosgun, et al.
Publicat: (2023-01-01)

Humoral and cellular immune responses to CoronaVac up to one year after vaccination
per: Priscilla Ramos Costa, et al.
Publicat: (2022-10-01)

Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination
per: Jianhua Li, et al.
Publicat: (2022-12-01)

Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
per: Samar Samoud, et al.
Publicat: (2023-08-01)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
per: Yun Shan Goh, et al.
Publicat: (2022-01-01)

Humoral responses to the CoronoVac vaccine in healthcare workers
per: Gokhan Eyupoglu, et al.
Publicat: (2023-02-01)

Immune Response to CoronaVac and Its Safety in Patients with Type 2 Diabetes Compared with Healthcare Workers
per: Bothamai Dechates, et al.
Publicat: (2023-03-01)

The safety and immunogenicity of a two-dose schedule of CoronaVac, and the immune persistence of vaccination for six months, in people living with HIV: A multicenter prospective cohort study
per: Yuxiao Wang, et al.
Publicat: (2023-03-01)

Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation
per: Eric Yuk Fai Wan, et al.
Publicat: (2024-09-01)

Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
per: Ruiqi Zhang, et al.
Publicat: (2022-04-01)

An Integrative Analysis of the Immune Features of Inactivated SARS-CoV-2 Vaccine (CoronaVac)
per: Zhujun Jiang, et al.
Publicat: (2022-05-01)

Metabolomics acts as a powerful tool for comprehensively evaluating vaccines approved under emergency: a CoronaVac retrospective study
per: Xinyu Liu, et al.
Publicat: (2023-07-01)

Waning anti-SARS-CoV-2 receptor-binding domain total antibody in CoronaVac-vaccinated individuals in Indonesia [version 2; peer review: 2 approved]
per: Samsul Anwar, et al.
Publicat: (2023-04-01)

Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group
per: Alejandro Escobar, et al.
Publicat: (2022-01-01)

Longitudinal evaluation of innate immune responses to three doses of CoronaVac vaccine
per: Cheng Cao, et al.
Publicat: (2023-10-01)

Risk of adverse events following CoronaVac's COVID-19 vaccination in women with and without autoimmunity
per: Stevent Sumantri, et al.
Publicat: (2023-03-01)

Immune Response to an Inactivated Vaccine of SARS-CoV-2 (CoronaVac) in an Indigenous Brazilian Population: A Cohort Study
per: Laís Albuquerque de Oliveira, et al.
Publicat: (2024-04-01)

Side effects of CoronaVac® COVID-19 vaccination: Investigation in North Jakarta district public health center communities in Indonesia
per: Diana Laila Ramatillah, et al.
Publicat: (2024-05-01)

Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial
per: Mine Durusu Tanriover, et al.
Publicat: (2022-11-01)

Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients
per: Michael Kwan Leung Yu, et al.
Publicat: (2024-12-01)

Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series
per: Nijasri C. Suwanwela, et al.
Publicat: (2022-01-01)

How has research on the effectiveness and safety of COVID-19 vaccination been evaluated: a scope review with emphasis on CoronaVac
per: Juan C. Alzate-Ángel, et al.
Publicat: (2024-04-01)

Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination
per: Almir Ribeiro da Silva Jr, et al.
Publicat: (2022-02-01)

Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
per: Suvichada Assawakosri, et al.
Publicat: (2024-01-01)

Acute prolonged motor aura resembling ischemic stroke after COVID − 19 vaccination (CoronaVac): the first case report
per: Wanakorn Rattanawong, et al.
Publicat: (2021-08-01)

Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity
per: Daniel Leung, et al.
Publicat: (2022-09-01)

Comparative Safety and Effectiveness of Heterologous CoronaVac–ChAdOx1 versus Homologous CoronaVac Vaccination in a Real-World Setting: A Retrospective Cohort Study
per: Ayakarn Ruenkham, et al.
Publicat: (2023-09-01)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
per: Hazal Cansu Çulpan, et al.
Publicat: (2023-12-01)

Absence of Anti-RBD Antibodies in SARS-CoV-2 Infected or Naive Individuals Prior to Vaccination with CoronaVac Leads to Short Protection of Only Four Months Duration
per: Camille F. de Oliveira, et al.
Publicat: (2022-04-01)

SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients
per: Yuxin Chen, et al.
Publicat: (2024-04-01)

Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients
per: Shiheng Wu, et al.
Publicat: (2023-02-01)

Hybrid Immunity Results in Enhanced and More Sustained Antibody Responses after the Second Sinovac-CoronaVac Dose in a Brazilian Cohort: DETECTCoV-19 Cohort
per: Bárbara Batista Salgado, et al.
Publicat: (2023-09-01)

Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report
per: Ekachai Singhatiraj, et al.
Publicat: (2021-09-01)

RESPOSTA CELULAR DE RESPONDEDORES E NÃO RESPONDEDORES ANTICÓRPICOS: ESTUDO EM PROFISSIONAIS DA SAÚDE VACINADOS COM CORONAVAC
per: Lais Teodoro da Silva, et al.
Publicat: (2023-10-01)

Sustained spike-specific IgG antibodies following CoronaVac (Sinovac) vaccination in sub-Saharan Africa, but increased breakthrough infections in baseline spike-naive individuals
per: Jackson Sembera, et al.
Publicat: (2023-11-01)

A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern
per: Bárbara M. Schultz, et al.
Publicat: (2022-08-01)

Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVac
per: Diego A. Díaz-Dinamarca, et al.
Publicat: (2024-08-01)

IMUNOFENOTIPAGEM DE LINFÓCITOS B EM RESPONDEDORES E NÃO RESPONDEDORES ANTICÓRPICOS: ESTUDO EM COORTE DE PROFISSIONAIS DA SAÚDE VACINADOS COM CORONAVAC
per: Juliana Ruiz Fernandes, et al.
Publicat: (2023-10-01)

Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster
per: Chin Shern Lau, et al.
Publicat: (2022-11-01)